LucyRx, a rapidly growing pharmacy benefits manager focused on improving access and outcomes in prescription care, has completed its acquisition of CerpassRx. This strategic move strengthens LucyRx’s ability to offer clinically focused, client-first solutions across a larger national footprint. With the addition of CerpassRx, LucyRx now supports over 1.5 million members and thousands of plan sponsors throughout the United States. The merger combines CerpassRx’s deep experience in cost-containment with LucyRx’s innovative technology, including its Care Guides, Formulary Marketplace, and proprietary AI platform, LucyIQ.
Health Technology Insights: Bridge to Life Names David Castiglioni CCO for VitaSmart US Launch
David Blair, Chief Executive Officer of LucyRx, said this acquisition is a significant milestone in the company’s mission to expand patient-focused care. He emphasized that the combination of innovation, clarity, and trusted service would allow LucyRx to better serve more employers and their members with a stronger platform built around clinical outcomes.
Health Technology Insights: OMRON Healthcare Surpasses 400 Million Blood Pressure Monitor Sales
As part of the transition, John Nicolosi, PharmD, who most recently served as Interim President of CerpassRx, has been named Chief Clinical Pharmacy Officer at LucyRx. With nearly 15 years of leadership experience in the PBM sector, Nicolosi will lead LucyRx’s growing suite of clinical programs and further the company’s commitment to better patient outcomes and care clarity.
The integration process is already underway with teams from both organizations working closely to ensure a smooth transition for clients, members, and staff. There will be no disruption in service—existing account teams, ID cards, and support channels will remain the same.
By joining forces, both companies bring complementary strengths to the table. CerpassRx offers a strong foundation in cost-saving strategies and long-standing client relationships, while LucyRx brings scale, technological innovation, and deeper clinical offerings. These include its Connected Specialty Care Network and tailored programs in key areas such as GLP-1 therapies and women’s health, which are designed to improve outcomes while managing costs effectively.
Susan Thomas, Chief Commercial Officer at LucyRx, said clients will continue to receive the support they trust while gaining access to a broader set of services. She noted that the partnership delivers added value through LucyRx’s enhanced clinical tools and increased transparency in prescription care.
Mark Newman, CEO and Co-Founder of Nomi Health, which previously oversaw CerpassRx, shared his confidence in LucyRx as the right partner to continue CerpassRx’s mission. He highlighted their shared commitment to transparency, innovation, and patient-centered service as key to delivering long-term value to clients and the healthcare industry as a whole.
John Nicolosi, now serving in a new leadership role at LucyRx, expressed his enthusiasm about continuing to serve clients and members on a larger scale. He said he has seen firsthand how the right pharmacy benefits partner can make a real difference. Nicolosi is focused on building upon that foundation to improve outcomes, reduce stress for families, and deliver meaningful savings.
This acquisition continues LucyRx’s momentum in transforming the pharmacy benefits space. It reinforces the company’s position as a partner committed to lowering prescription costs, enhancing access, and providing clear, effective support for both employers and members.
Health Technology Insights: Lupin Acquires VISUfarma to Boost Global Ophthalmology Business
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
